Epigallocatechin gallate inhibits the growth and promotes the apoptosis of bladder cancer cells

被引：16

作者：

Feng, Chenchen ^{[1
]}

Ho, Yatfaat ^{[1
]}

Sun, Chuanyu ^{[1
]}

Xia, Guowei ^{[1
]}

Ding, Qiang ^{[1
]}

Gu, Bin ^{[1
]}

机构：

[1] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai 200040, Peoples R China

来源：

EXPERIMENTAL AND THERAPEUTIC MEDICINE | 2017年 / 14卷 / 04期

关键词：

epigallocatechin gallate; tissue factor pathway inhibitor 2; bladder cancer; methylation; FACTOR PATHWAY INHIBITOR-2; TUMOR-SUPPRESSOR GENE; TEA POLYPHENOL; IN-VITRO; (-)-EPIGALLOCATECHIN GALLATE; HEPATOCELLULAR-CARCINOMA; EGCG; ANGIOGENESIS; EXPRESSION; TFPI-2;

D O I：

10.3892/etm.2017.4981

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Epigallocatechin gallate (EGCG) has been revealed to inhibit the proliferation and induce the apoptosis of several types of tumor, in addition to inhibiting DNA methyltransferase activity, leading to CpG demethylation. Tissue factor pathway inhibitor 2 (TFPI-2) expression is downregulated in bladder cancer. The present study revealed that this downregulation was partly due to hypermethylation of the TFPI-2 gene promoter, which was decreased by EGCG treatment. In addition, the present study demonstrated that EGCG could inhibit the viability and invasion, and induce the apoptosis, of bladder cancer T24 cells. Furthermore, western blot analysis and reverse transcription-quantitative polymerase chain reaction analyses demonstrated that EGCG could upregulate the expression of TFPI-2. These results suggest that EGCG inhibits the growth and induces the apoptosis of bladder cancer cells through restoring TFPI-2 expression. Thus, EGCG is a potential therapeutic candidate for the treatment of bladder cancer.

引用

页码：3513 / 3518

页数：6

共 38 条

[1] Cancer microvesicles induce tissue factor-related procoagulant activity in endothelial cells in vitro [J].

Adesanya, Mufuliat Adeola ;

Maraveyas, Anthony ;

Madden, Leigh A. .

BLOOD COAGULATION & FIBRINOLYSIS, 2017, 28 (05) :365-372

[2] Secretome-Based Identification of TFPI2, A Novel Serum Biomarker for Detection of Ovarian Clear Cell Adenocarcinoma [J].

Arakawa, Noriaki ;

Miyagi, Etsuko ;

Nomura, Ayako ;

Morita, Erina ;

Ino, Yoko ;

Ohtake, Norihisa ;

Miyagi, Yohei ;

Hirahara, Fumiki ;

Hirano, Hisashi .

JOURNAL OF PROTEOME RESEARCH, 2013, 12 (10) :4340-4350

[3]

Borska S, 2003, FOLIA HISTOCHEM CYTO, V41, P229

[4] Telomere maintenance in childhood primitive neuroectodermal brain tumors [J].

Didiano, D ;

Shalaby, T ;

Lang, D ;

Grotzer, MA .

NEURO-ONCOLOGY, 2004, 6 (01) :1-8

[5]

Esmaeili Mohammad Ali, 2016, Journal of Chemical Biology, V9, P41, DOI 10.1007/s12154-015-0144-2

[6] Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate [J].

Fassina, G ;

Venè, R ;

Morini, M ;

Minghelli, S ;

Benelli, R ;

Noonan, DM ;

Albini, A .

CLINICAL CANCER RESEARCH, 2004, 10 (14) :4865-4873

[7] Expression of pigment epithelium-derived factor and tumor necrosis factor-α is correlated in bladder tumor and is related to tumor angiogenesis [J].

Feng, Chen-chen ;

Wang, Pao-hsun ;

Ding, Qiang ;

Guan, Ming ;

Zhang, Yuan-fang ;

Jiang, Hao-wen ;

Wen, Hui ;

Wu, Zhong .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (02) :241-246

[8]

Feng CC, 2016, J BUON, V21, P1518

[9] Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation [J].

Feng, Chenchen ;

Ding, Guanxiong ;

Jiang, Haowen ;

Ding, Qiang ;

Wen, Hui .

TUMOR BIOLOGY, 2015, 36 (05) :3457-3464

[10] PI3Kβ Inhibitor TGX221 Selectively Inhibits Renal Cell Carcinoma Cells with Both VHL and SETD2 mutations and Links Multiple Pathways [J].

Feng, Chenchen ;

Sun, Yang ;

Ding, Guanxiong ;

Wu, Zhong ;

Jiang, Haowen ;

Wang, Lujia ;

Ding, Qiang ;

Wen, Hui .

SCIENTIFIC REPORTS, 2015, 5

← 1 2 3 4 →